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Abstract
High grade astrocytomas such as anaplastic astrocytoma and glioblastoma multiforme are
aggressive central nervous system malignancies with a poor prognosis. Due to shortened
survival times, their devastating effects are usually localized intracranially and rarely
metastasize outside of the central nervous system. When metastases occur, they usually present
in patients with longer survival times and they typically coincide with a primary site
recurrence. We present a rare case of metastases from a high-grade astrocytoma/glioblastoma
to the pleura, bones and liver within six months of diagnosis, without primary site recurrence.
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High-grade astrocytomas or glioblastomas are aggressive primary central nervous system (CNS)
tumors with overall poor prognosis. They are typically divided into three categories: anaplastic
astrocytomas, anaplastic oligodendroglioma and glioblastoma multiforme and are graded from
III-IV [1]. Glioblastomas are four times more common than anaplastic astrocytomas, with
incidences of around two to three per 10,000 people in the United States [2]. Glioblastomas fare
worse in prognosis with median overall survival of only around 12 months, compared to
anaplastic astrocytomas with median survival of around two to three years [3]. These tumors
usually remain confined to a localized area and rarely metastasize outside of the CNS [3].
However, extracranial metastases have been surmised in the literature to occur in 0.44-2% of
these patients [4-6]. Pleuropulmonary metastasis from an intracranial glioblastoma is
exceedingly rare, often due to the shortened survival of these patients. Additionally, metastases
usually occur in the setting of primary site reoccurrence or progression. We describe a case of
previously diagnosed high-grade astrocytoma with presentation of metastases only six months
after initial diagnosis with extra-CNS metastases to the pleura, liver and bone without primary
site recurrence.
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A 56-year-old Caucasian male with past medical history of a high-grade astrocytoma of the
right temporal lobe presented to the oncology clinic with dyspnea and palpitations for several
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weeks. He had been diagnosed with high-grade astrocytoma six months prior, which was
treated with surgical resection and was followed by concurrent chemotherapy and radiation for
six weeks with temozolomide with subsequent maintenance temozolomide. Pathology from his
original brain tumor noted mixed features of an anaplastic pleomorphic xanthoastrocytoma
(PXA) with atypical features versus glioblastoma. The pathologist described an astrocytic
neoplasm composed of cells with variable polymorphism, brisk mitotic activity including
atypical forms, and necrosis were present. Immunohistochemistry (IHC) stains were positive for
glial fibrillary acidic protein (GFAP), oligodendroglial lineage 2 (OLIG2) and cellular
differentiation 34 marker (CD34). The tumor did not harbor isocitrate dehydrogenase 1 (IDH-1),
methylguanine-DNA methyltransferase (MGMT) or B-raf proto-oncogene serine/threonine
kinase (BRAF) mutations.
Upon presentation to our clinic, the patient was still receiving maintenance therapy with
temozolomide 200 mg/m2 on days one through five every 28 days. On physical exam, he was
found to be tachycardic with a heart rate in the 150s with an irregularly irregular rhythm. On
physical exam, he was noted to have decreased breath sounds to auscultation on the right and
dullness to percussion in the mid to lower right hemithorax. He was admitted to the hospital for
further evaluation. Computed tomography (CT) of the chest showed a pulmonary embolus in
the left pulmonary artery in addition to a large pleural effusion on the right with pleural
thickening and a nodular appearance. There was a new hypodense lesion in the superior part of
the liver measuring 2.7 x 2.3 cm with multiple lytic bone lesions on CT of the abdomen. A bone
scan confirmed the metastatic nature of bone lesions. Magnetic resonance imaging (MRI) of the
brain showed abnormal enhancement in the middle cranial fossa, which was thought to be
related to prior treatment. Anti-coagulation with heparin was initiated for treatment of the
pulmonary embolus. Thoracentesis revealed the effusion to be exudative and cytology was
significant for atypical cells. Thoracoscopy was performed for pleural biopsy and on
examination, classic pleural studding was noted (Figure 1). Pleural biopsies were obtained
using rigid optical forceps. Biopsy report showed malignant cells with initial IHC stains
negative for calretinin, carcinoembryonic antigen (CEA), cytokeratin 5/6 (CK 5/6), pankeratin,
thyroid transcription factor 1 (TTF-1) and Wilms tumor protein (WT-1), as is usually done to
rule out lung carcinoma or mesothelioma. Because of marked pleomorphism in the sample
which is normally seen in glioblastoma or high grade astrocytomas, glial fibrillary acidic protein
(GFAP) by IHC was checked and found to be positive. Additionally, S100 (acidic protein, which is
a common marker for neural tissue and melanoma) by IHC was also positive (Figure 2). Coupled
together, these findings were consistent with metastasis from his known diagnosis of high
grade astrocytoma/glioblastoma. The patient had placement of a PleurxTM catheter and was
discharged home on anticoagulation therapy. Upon discharge and finalization of pathology
report, the patient was offered chemotherapy with bevacizumab, but the patient opted to be
placed in hospice and subsequently died a few weeks later.
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FIGURE 1: Photographs of the pleural space obtained during
thoracoscopy show numerous nodules studding the pleura
(indicated by arrows), suggestive of metastatic disease.

FIGURE 2: Histologic findings of the pleural biopsy show
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pleomorphic astrocytic tumor cells (notable for vacuolization of
the neoplastic cells and indicated by the arrows) compatible
with a pleomorphic high-grade astrocytoma (hematoxylineosin, 100× 200× and 400× original magnification).

Discussion
Malignant gliomas are some of the most common brain tumors and generally have a poor
prognosis [6]. Treatment includes a combination of surgical resection, radiation and cytotoxic
chemotherapy. These gliomas are graded from I to IV and this is based on various
histopathologic features such as atypia, necrosis and mitoses. Grade I tumors are considered
benign while higher grades such as III and IV are considered malignant with a worse
prognosis. These tumors are subcategorized into three different types: anaplastic astrocytoma
(AA), anaplastic oligodendroglioma (AO) and glioblastoma multiforme (GBM). Anaplastic
astrocytomas are grade III tumors which histologically have anaplasia and mitotic activity.
Grade IV tumors, or glioblastomas, are histologically different in that they typically have
microvascular proliferation and/or necrosis on pathologic specimens [1]. Of note, our patient
was noted to have a high-grade astrocytoma, which was thought to be either high grade
glioblastoma or pleomorphic xanthoastrocytoma (PXA) with atypical features [7]. PXAs are rare,
accounting for less than 1% of gliomas, and are typically described as superficial astrocytic
neoplasms, with histologic features of marked cellular pleomorphism and frequent
xanthomatous change [8]. They are typically recognized as grade II gliomas but there are
instances of aggressive variants with anaplastic changes and reports of transformation to
glioblastomas [8,9]. Malignant gliomas in general remain localized to the central nervous
system and do not typically metastasize outside of the brain, likely related to their shortened
survival times. Metastases are exceedingly rare, initially estimated at 0.44% but has steadily
increased to 2% of all GBM cases in recent years [4-6]. The median time for appearance of
metastases is around two years from time of diagnosis [6]. Additionally, unlike our case,
metastases usually coincide with recurrence or progression of the primary tumor site [10]. One
review of the literature found 128 cases of metastatic GBM prior to 2008, which noted that the
most common sites of spread occurred in the pleura (60%), regional lymph nodes (51%), bones
(31%) and liver (25%) [5]. The increasing incidence of metastases outside of the central nervous
system may potentially be explained by multiple factors, including the improvement in our
imaging and diagnostic abilities to detect metastases in addition to newer treatment modalities
and the improved overall survival of patients, which may take time for the metastatic cells to
grow.
There are many hypotheses that attempt to explain why this particular type of tumor usually
does not spread beyond the brain parenchyma. One hypothesis notes that the rarity of
metastases may be explained both by shortened overall survival in addition to the peculiarity of
the brain lymphatic system [4,11]. The blood-brain barrier is theorized to prevent migration of
malignant cells outside of the CNS. However, malignant gliomas can utilize several
mechanisms for metastases, including hematogenous spread via vessels of the primary tumor,
hematogenous spread from invasion of the dural veins, hematogenous and lymphogenous
spread by infiltrating the skull and extracranial soft tissues, spread via cerebrospinal fluid, and
lastly, spread by ventricular shunting (ventriculoatrial or ventriculo-pleural shunts) [5]. With
the improvement in treatment modalities over recent years, GBM cells may have more time to
escape the CNS via shedding to lymphatic and hematological systems [11], though extracranial
spread could also occur by contamination of blood during surgical tumor resection [12]. Huang
et al. reported that about 96% of GBM patients with extracranial metastases previously
underwent neurosurgical procedures [13]. Genetic derangements and molecular structures may
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also be a part in determining which patients will likely develop extracranial metastases [6].
Anti-angiogenic therapy has been reported as having a possible association with development
of extracranial metastases [11].

Conclusions
In conclusion, extracranial metastasis of high grade astrocytomas is very rare. Lung, lymph
nodes, and bone are among the most commonly affected sites. It may or may not occur with a
recurrence at the primary tumor site. The radiologic and clinical findings are nonspecific and it
can mimic any other metastatic disease. Time to onset of metastases usually occurs in those
patients with longer survivals. A high degree of suspicion is needed for early diagnosis and
management of patients with this disease in order to hasten diagnosis, management and
ultimately, survival.
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